AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyInterventionalTrial registry
ABP 692 vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: Phase of Research Unknown
A study involved 152 individuals with relapsing-remitting multiple sclerosis (RRMS) receiving either ABP 692 or Ocrelizumab. The pharmacokinetic similarity between ABP 692 and both versions of Ocrelizumab was assessed, but results have not yet been published.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the pharmacokinetics of new drugs like ABP 692 compared to established treatments like Ocrelizumab could inform treatment decisions and drug development.
What this does not prove
No results are published, and the study is currently listed as Active, Not Recruiting, limiting available information about outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 152 · actual
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
- Trial registrationComparison Between ABP 692 and Ocrevus® (Ocrelizumab) ↗
Supporting passages (15)
study design"studyType": "INTERVENTIONAL"
subjects"description": "Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15.
sample size"count": 152, "type": "ACTUAL"
sample size basis"type": "ACTUAL"
randomized"allocation": "RANDOMIZED"
controlled"type": "ACTIVE_COMPARATOR"
peer reviewed"isFdaRegulatedDrug": true
regulatory approval"isFdaRegulatedDrug": true
regulatory approval details"isFdaRegulatedDrug": true
relevant ms types"description": "Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15.
intervention"description": "Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15.
comparator"label": "Ocrelizumab (EU)"
primary endpoint"measure": "Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)",
findings"briefSummary": "The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU)."
limitationsNo results are posted.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.